Agilent Technologies A
Agilent Technologies is a life sciences company that provides instruments, software, and consumables for diagnostic laboratories, pharmaceutical research, and chemical analysis. Agilent shows solid financial health (ND/EBITDA 1.15, operating margin 25.56%) and high quality (ROE 20.97%), but its valuation is demanding (P/E 34.15) and growth is moderate (8.1% revenue), limiting appeal at these prices.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Agilent Technologies is a life sciences company that provides instruments, software, and consumables for diagnostic laboratories, pharmaceutical research, and chemical analysis. Agilent shows solid financial health (ND/EBITDA 1.15, operating margin 25.56%) and high quality (ROE 20.97%), but its valuation is demanding (P/E 34.15) and growth is moderate (8.1% revenue), limiting appeal at these prices.
Score by category
| Category | Score |
|---|---|
| Financial health | 7.8 |
| Quality / Moat | 7.1 |
| Valuation | 3.4 |
| Growth | 6.2 |
| Dividend | 4.2 |
| Momentum | 6.9 |
| Risk & Context | 4.8 |
OVERALL SCORE: 5.8/10
Context and risks
The rise in 10-year Treasury yields (5.17%) affects Agilent due to its high P/E (34.15), which discounts distant cash flows. However, its net debt/EBITDA of 1.15 is moderate, limiting the impact. The effect is contained and not dominant.
News considered in the analysis
- Agilent Technologies (A) Tests Valuation On Exchange Offer And Recurring Revenue Story — La noticia destaca una valoración exigente (PER 34.15) y un posible canje de deuda que podría diluir o afectar la estructura de capital, aunque el impacto es moderado y parte ya está en el precio.
- Agilent (A) Up 9.6% Since Last Earnings Report: Can It Continue? — El movimiento alcista post-resultados ya está descontado en el precio, sin información nueva que justifique un ajuste adicional.
- 3 Healthcare Stocks That Fall Short — Listículo genérico sin información específica sobre Agilent; ruido.
- Is Bullfrog AI Holdings Inc. (BFRG) Outperforming Other Medical Stocks This Year? — Comparativa con otra empresa sin relevancia para Agilent; ruido.
- If You Invested $1000 in Agilent Technologies a Decade Ago, This is How Much It'd Be Worth Now — Contenido promocional sin información nueva; ruido.
Verdict: Hold; business quality is high, but valuation offers no margin of safety for new entries.
Main risk: The main risk is the demanding valuation (P/E 34.15, EV/EBITDA 24.57) which, combined with moderate growth, leaves little room for error if expectations are not met or rates keep rising.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →